Literature DB >> 24574499

Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation.

Joshua S Woodworth1, Claus Sindbjerg Aagaard, Paul R Hansen, Joseph P Cassidy, Else Marie Agger, Peter Andersen.   

Abstract

CD4 T cells are crucial to the control of Mycobacterium tuberculosis infection and are a key component of current vaccine strategies. Conversely, immune-mediated pathology drives disease, and recent evidence suggests that adaptive and innate responses are evolutionarily beneficial to M. tuberculosis. We compare the functionality of CD4 T cell responses mounted against dominant and cryptic epitopes of the M. tuberculosis 6-kDa early secreted Ag (ESAT-6) before and postinfection. Protective T cells against cryptic epitopes not targeted during natural infection were induced by vaccinating mice with a truncated ESAT-6 protein, lacking the dominant epitope. The ability to generate T cells that recognize multiple cryptic epitopes was MHC-haplotype dependent, including increased potential via heterologous MHC class II dimers. Before infection, cryptic epitope-specific T cells displayed enhanced proliferative capacity and delayed cytokine kinetics. After aerosol M. tuberculosis challenge, vaccine-elicited CD4 T cells expanded and recruited to the lung. In chronic infection, dominant epitope-specific T cells developed a terminal differentiated KLRG1(+)/PD-1(lo) surface phenotype that was significantly reduced in the cryptic epitope-specific T cell populations. Dominant epitope-specific T cells in vaccinated animals developed into IFN-γ- and IFN-γ,TNF-α-coproducing effector cells, characteristic of the endogenous response. In contrast, cryptic epitope-specific CD4 T cells maintained significantly greater IFN-γ(+)TNF-α(+)IL-2(+) and TNF-α(+)IL-2(+) memory-associated polyfunctionality and enhanced proliferative capacity. Vaccine-associated IL-17A production by cryptic CD4 T cells was also enhanced, but without increased neutrophilia/pathology. Direct comparison of dominant/cryptic epitope-specific CD4 T cells within covaccinated mice confirmed the superior ability of protective cryptic epitope-specific T cells to resist M. tuberculosis infection-driven T cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574499     DOI: 10.4049/jimmunol.1300283

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.

Authors:  Cesar Boggiano; Katrin Eichelberg; Lakshmi Ramachandra; Jaqueline Shea; Lalita Ramakrishnan; Samuel Behar; Joel D Ernst; Steven A Porcelli; Markus Maeurer; Hardy Kornfeld
Journal:  Vaccine       Date:  2017-05-02       Impact factor: 3.641

2.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 3.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

4.  Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection.

Authors:  Peter Hart; Alastair Copland; Gil Reynolds Diogo; Shane Harris; Ralf Spallek; Wulf Oehlmann; Mahavir Singh; Juan Basile; Martin Rottenberg; Matthew John Paul; Rajko Reljic
Journal:  Mol Ther       Date:  2017-12-22       Impact factor: 11.454

Review 5.  Th1 cytokines, true functional signatures for protective immunity against TB?

Authors:  Gucheng Zeng; Guoliang Zhang; Xinchun Chen
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

6.  Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.

Authors:  Yushi Yao; Rocky Lai; Sam Afkhami; Siamak Haddadi; Anna Zganiacz; Fatemeh Vahedi; Ali A Ashkar; Charu Kaushic; Mangalakumari Jeyanathan; Zhou Xing
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

Review 7.  Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis.

Authors:  Kevin B Urdahl
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

8.  Antigen signal strength during priming determines effector CD4 T cell function and antigen sensitivity during influenza virus challenge.

Authors:  Mika Nagaoka; Yasuko Hatta; Yoshihiro Kawaoka; Laurent P Malherbe
Journal:  J Immunol       Date:  2014-08-01       Impact factor: 5.422

9.  Reprogramming the T Cell Response to Tuberculosis.

Authors:  Joshua S Woodworth; Peter Andersen
Journal:  Trends Immunol       Date:  2016-01-05       Impact factor: 16.687

Review 10.  Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis.

Authors:  Shunsuke Sakai; Katrin D Mayer-Barber; Daniel L Barber
Journal:  Curr Opin Immunol       Date:  2014-08       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.